| Literature DB >> 36012901 |
Martina Ferrillo1, Mario Migliario2, Nicola Marotta3, Lorenzo Lippi4,5, Alessandro Antonelli1, Dario Calafiore6, Valerio Ammendolia3, Leonzio Fortunato1, Filippo Renò7, Amerigo Giudice1, Marco Invernizzi4,5, Alessandro de Sire3.
Abstract
Breast cancer (BC) survivors treated with aromatase inhibitors (AIs) commonly show several pathological issues, including poor oral health, bone health impairment, and vitamin D deficiency. However, to date, oral health issues in BC survivors treated with AIs have been poorly investigated and their relationship with vitamin D deficiency are far from being understood. This study aimed to evaluate the correlation between oral health and vitamin D status in BC survivors undergoing treatment with AIs through a machine learning approach. In this cross-sectional study, we included post-menopausal BC women with vitamin D deficiency undergoing AIs therapy. The outcome measures were the following: oral health indexes as the Decayed, Missing, and Filled Permanent Teeth Index (DMFT); serum levels of 25(OH)D3; Bone Mineral Density (BMD); and the diagnosis of osteoporosis. We included 41 post-menopausal BC women, mean aged 66.10 ± 8.47 years, with mean serum levels of vitamin D of 14.63 ± 6.62 ng/mL. Furthermore, 56.10% of patients had a diagnosis of osteoporosis and 36.59% were osteopenic. DMFT was significantly related to smoking (p-value = 0.005) and dental floss use (p-value = 0.001). There was a significant correlation between DMFT and vitamin D levels (Pearson's r: -0.73; p-value = 0.001). The regression machine learning model showed that vitamin D status and the use of dental floss were the most relevant variables in terms of correlation with DMFT. In conclusion, vitamin D deficiency, inadequate use of dental floss, and smoking had a negative impact on oral health in BC women. Thus, vitamin D deficiency screening and supplementation and a prompt oral rehabilitation plan should be suggested and implemented in the complex treatment framework of BC survivors undergoing treatment with AIs.Entities:
Keywords: bone loss; breast cancer; cancer treatment-induced bone loss; oral health; osteoporosis; periodontal disease; rehabilitation; vitamin D
Year: 2022 PMID: 36012901 PMCID: PMC9410090 DOI: 10.3390/jcm11164662
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Figure 1Correlation among oral health, bone mineral density, and vitamin D status.
Study population characteristics (n = 41).
| Mean age (years) | 66.1 ± 8.47 |
| BMI (kg/m2) | 24.83 ± 4.41 |
| Smokers ( | 12 (29.27%) |
| Grading | |
| G1 ( | 5 (12.20%) |
| G2 ( | 26 (63.41%) |
| G3 ( | 10 (24.39%) |
| HER2 ( | 9 (21.95%) |
| Ki-67 | |
|
| 24 (58.54%) |
|
| 7 (17.07%) |
| RT ( | 31 (75.61%) |
| HT ( | 41 (100.00%) |
| CT ( | 17 (41.46%) |
| BCRL ( | 9 (21.95%) |
| AWS ( | 13 (31.71%) |
Continuous variables are expressed as means ± standard deviations; categorical variables are expressed as counts (percentages). Abbreviations: HER2/neu: Human Epidermal Growth Factor Receptor 2; RT: radiotherapy; HT: hormone therapy; CT: chemotherapy; BCRL: Breast Cancer related-lymphedema; AWS: Axillary web syndrome.
Vitamin D status and bone health outcomes in the study population (n = 41).
| Serum 25OH-Vit.D (ng/mL) | 14.63 ± 6.62 |
| Serum 25(OH)vit. D ≥ 20 and <30 ng/mL ( | 10 (24.39%) |
| Serum 25(OH)vit. D ≥ 10 and <20 ng/mL ( | 21 (51.22%) |
| Serum 25(OH)vit. D < 10 ng/mL ( | 10 (24.39%) |
| Serum calcium (mg/dL) | 9.23 ± 0.54 |
| Serum PTH (pg/mL) | 43.5 ± 12.24 |
| LS BMD (g/cm2) | 0.92 ± 0.19 |
| LS Tscore | −1.91 ± 1.31 |
| LS Zscore | −0.45 ± 1.29 |
| FN BMD (g/cm2) | 0.74 ± 0.1 |
| FN Tscore | −1.94 ± 0.89 |
| FN Zscore | −0.54 ± 0.83 |
| Osteoporosis ( | 23 (56.10%) |
| Osteopenia ( | 15 (36.59%) |
Continuous variables are expressed as means ± standard deviations; categorical variables are expressed as counts (percentages). Abbreviations: 25(OH)vit. D: 25-hydroxy-vitamin D; PTH: parathyroid hormone; LS: lumbar spine; BMD: bone mineral density; FN: femoral neck.
Oral hygiene status in the study population (n = 41).
| Manual toothbrush ( | 28 (68.29%) |
| Electric toothbrush ( | 13 (31.71%) |
| Dental floss ( | 16 (39.02%) |
| DMFT | 17.44 ± 6.76 |
| OHI | |
|
| |
|
| |
|
| |
| PCR | |
|
| |
|
| |
|
| |
|
| |
| PSR | |
|
| |
|
| |
|
| |
|
| |
| WTCI | |
|
| |
|
| |
|
|
Continuous variables are expressed as means ± standard deviations; categorical data are expressed as counts (%). Abbreviations: DMFT = Decayed, Missing and Filled Permanent Teeth; OHI = Oral Hygiene Index; PCR = Plaque Control and Record; PSR = Periodontal Screening and Recording; WTCI = Winkel Tongue Coating Index.
Univariate Logistic regression between the Decayed, Missing, and Filled Permanent Teeth Index (DMFT), oral hygiene habits, and breast cancer characteristics.
| Variable | Odd Ratio (95% CI) | |
|---|---|---|
| Smoke | 1.17 (1.03–1.32) | 0.005 * |
| Manual toothbrush use | 0.83 (0.73–1.11) | 0.052 |
| Electric toothbrush use | 0.84 (0.75–1.09) | 0.052 |
| Dental floss use | 0.83 (0.73–0.95) | 0.001 * |
| HER2 | 1.05 (0.94–1.18) | 0.522 |
| Ki-67 | 1.01 (0.92–1.10) | 0.643 |
| RT | 0.96 (0.86–1.07) | 0.651 |
| HT | 1.06 (0.94–1.19) | 0.532 |
| CT | 0.97 (0.88–1.06) | 0.522 |
| BCRL | 1.01 (0.91–1.13) | 0.573 |
| AWS | 1.06 (0.96–1.17) | 0.647 |
Abbreviations: CI: confidence interval; HER2: Human Epidermal Growth Factor Receptor 2; RT: radiotherapy; HT: hormone therapy; CT: chemotherapy; AWS: Axillary web syndrome; BCRL: Breast Cancer-Related Lymphedema; * = p value <0.05.
Variable importance in regression random forest model in terms of correlation with Decayed, Missing, and Filled Permanent Teeth Index (DMFT).
| Mean Decrease in Accuracy | Total Increase in Node Purity | |
|---|---|---|
| 25OH-Vit.D serum levels | 0.22 | 1.46 |
| Dental floss | 0.08 | 1.36 |
| Smoke | 0.11 | 0.99 |
| HER2 | 0.06 | 0.50 |
| BCRL | 0.00 | 0.39 |
| CT | 0.00 | 0.34 |
| Toothbrush | −0.02 | 0.30 |
| Ki-67 | −0.01 | 0.27 |
| AWS | 0.00 | 0.21 |
| RT | −0.01 | 0.16 |
| HT | 0.00 | 0.00 |
Abbreviations: 25(OH)vit. D: 25-hydroxy-vitamin D; HER2: Human Epidermal Growth Factor Receptor 2; BCRL: Breast Cancer-Related Lymphedema; CT: chemotherapy; AWS: Axillary web syndrome; RT: radiotherapy; HT: hormone therapy.